Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. April 2026 07:00 ET | Quelle: Foghorn Therapeutics, Inc.

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical...
09. April 2026 07:00 ET | Quelle: Rani Therapeutics, LLC

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
09. April 2026 03:30 ET | Quelle: Kainova Therapeutics

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

Kainova Therapeutics has dosed the first European patient in its Phase I/II DOMISOL trial of DT-7012, advancing its Treg-depleting immunotherapy program.
08. April 2026 08:00 ET | Quelle: UroGen Pharma Ltd.

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

UroGen Launches LG-UTUC Luminaries Initiative recognizing clinicians and institutions working to achieve excellence in LG-UTUC care.
08. April 2026 08:00 ET | Quelle: Remedy Plan Therapeutics

Remedy Plan Therapeutics Appoints Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer

GAITHERSBURG, Md., April 08, 2026 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics, a clinical-stage biotechnology company developing novel therapies that target fundamental metabolic vulnerabilities in...
08. April 2026 06:52 ET | Quelle: Research and Markets

Pharmacogenomics Market Research and Global Forecast Report 2026-2032: Transition from Specialized Research to Mainstream Diagnostics and Therapeutics Fuels Industry Growth

Dublin, April 08, 2026 (GLOBE NEWSWIRE) -- The "Pharmacogenomics Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Pharmacogenomics Market is...
08. April 2026 06:00 ET | Quelle: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306...
06. April 2026 11:43 ET | Quelle: Biodesix, Inc.

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

LOUISVILLE, Colo., April 06, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that the company will present seven abstracts, including...
06. April 2026 07:00 ET | Quelle: BioCryst Pharmaceuticals, Inc.

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) --...
06. April 2026 03:54 ET | Quelle: Mordor Intelligence

IoT in Healthcare Market Led by Home-Care Segment Growing at an 18.32% CAGR; to Reach USD 483.72 Billion by 2031, Reports Mordor Intelligence

The falling sensor costs and edge analytics are accelerating IoT adoption across hospitals and home‑care healthcare settings globally.

Vorherige Seite

Nächste Seite